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and Michael Berk1,8,9Abstract
Background: Historically, the focus of Non Communicable Disease (NCD) prevention and control has been
cardiovascular disease (CVD), type 2 diabetes mellitus (T2DM), cancer and chronic respiratory diseases. Collectively,
these account for more deaths than any other NCDs. Despite recent calls to include the common mental disorders
(CMDs) of depression and anxiety under the NCD umbrella, prevention and control of these CMDs remain largely
separate and independent.
Discussion: In order to address this gap, we apply a framework recently proposed by the Centers for Disease
Control with three overarching objectives: (1) to obtain better scientific information through surveillance, epidemiology,
and prevention research; (2) to disseminate this information to appropriate audiences through communication and
education; and (3) to translate this information into action through programs, policies, and systems. We conclude that a
shared framework of this type is warranted, but also identify opportunities within each objective to advance this
agenda and consider the potential benefits of this approach that may exist beyond the health care system.
Keywords: Non-Communicable Disease, Common mental disorders, Prevention, Depression, Anxiety, Cardiovascular
disease, Type 2 diabetes mellitus, Co-morbidityBackground
The World Health Organization (WHO) defines Non-
Communicable Diseases (NCDs) as medical conditions
that cannot be transmitted. They are primarily character-
ized by chronicity of at least 3-months and their progres-
sive nature [1]. While this definition encapsulates a host
of medical conditions, the focus of NCD prevention and
control has largely remained on the four conditions that,
when combined, account for more deaths than any other:
cardiovascular disease (CVD), type 2 diabetes mellitus
(T2DM), cancer and chronic respiratory diseases. These
conditions are known as the “Big Four.” However, there
have been increasing calls to expand the NCD umbrella
to include the common mental disorders (CMDs) of* Correspondence: adrienne.oneil@unimelb.edu.au
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unless otherwise stated.depression and anxiety [2,3]. While some have further
proposed the inclusion of severe mental disorders (e.g.
dementia, schizophrenia and bipolar; the latter two of
particular significance given evidence of their shared
risk factors, pathways and co-morbidity with NCDs and
CMDs), the focus of this paper will be confined to the
CMDs, due to their major contribution to the global
disease burden. Indeed, the WHO’s Global Action Plan
(2013–20) to reduce the global burden of NCDs and
preventable mortality now incorporates mental disorder
prevention and control targets [4]. However, efforts to
curb mental and physical disease still remain largely
separate and independent of one another. In an attempt
to close this gap, the Centers of Disease Control and
Prevention [5] has recently released a public health action
plan that aims to integrate mental health promotion and
mental illness prevention with chronic disease prevention
(see Table 1). Briefly, this framework comprises eight
strategies with three overarching objectives: (1) to ob-
tain better scientific information through surveillance,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Eight framework components of the CDC
Description of framework objectives
1. Surveillance to develop shared operational definitions and
determinants of mental illness
2. Epidemiological research into determinants and protective
factors for mental health and their relationships to chronic
diseases
3. Prevention research to determine the importance of mental
illness/health as factors in public health promotion and
prevention
4. Communication to develop culturally, linguistically, and
developmentally appropriate educational products
5. Education of Health Professionals including the development
of appropriate education plans for professional audiences
6. Program Integration Support at various jurisdictional levels
7. Policy Integration that involves the development of policies
at all government levels for all audiences and stakeholders
8. Systems to Promote Integration such as establish systems
integration to promote program and policy integration
across multiple infrastructures
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this information to appropriate audiences through com-
munication and education; and (3) to translate this in-
formation into action through programs, policies, and
systems. With a specific focus on the CMDs, this paper
argues that implementation of this shared framework is
warranted, but also aims to identify opportunities within
each objective to advance this agenda. These include: i)
greater intellectual and financial investment in research
focused on the primary prevention of CMDs as a key
strategy for minimizing subsequent NCD risk by delaying
or preventing its onset; ii) re-conceptualising the discourse
around CMDs to reflect their symbiotic relationship with
the NCDs; iii) appropriate education of health profes-
sionals, patients and stakeholders; and iv) the integration
of interventions and programs that consider context, cost
and responsibility. We conclude by considering the poten-
tial benefits of this approach beyond the health care
system.
Is a shared framework for CMD and NCD prevention and
control warranted?
The statement there is “no health without mental
health” [6] has been globally endorsed by authoritative
health bodies. Indeed, we have previously argued this
adage should be reflected within the NCD umbrella by
including CMDs for three key reasons. First, when the
global burden of disease is viewed in terms of disability,
and not death, major depression is the second leading
cause of disability. By comparison, the Big 4 account for
only half (54%) of all NCD-related disability adjusted life
years (DALYs). A recent report suggests the annual cost
of depression is $200 billion in the United States alone[7], which is compounded by the impact of anxiety dis-
orders that often co-occur. Anxiety is the most common
mental illness in the United States, affecting 40 million
individuals [8]. Second, from an etiological perspective,
CMDs and NCDs are strongly inter-connected, highly
co-morbid and share important pathways to disease. It
is well established those with a mental disorder are
more likely to have a medical condition [9], while indi-
viduals with a somatic condition such as T2DM, are at
increased risk of a mental disorder such as depression
[10] or anxiety [11]. For example, mental disorders and
CVD, the two dominant contributors to the global eco-
nomic burden of NCDs [12], share a close relationship.
The presence of a clinical depressive disorder elevates the
risk of incident CVD [13]. A meta-analysis also revealed
individuals with anxiety disorders are at increased risk of
incident CVD and cardiac death [14]. In addition to men-
tal disorders, specific depressive and anxiety sub-types
contribute to adverse cardiac-related outcomes. Somatic
subtypes of anxiety disorder can predict coronary heart
disease (CHD) while cognitive subtypes contribute to in-
hospital cardiac complications in acute coronary syn-
drome (ACS) patients, independently of depression [15].
The converse is also true; a cardiac event elevates a pa-
tient’s risk of developing depression and anxiety. Thus, the
American Heart Association recently recognized depres-
sion as a risk factor for poor prognosis following a cardiac
event [16]. Similar bi-directional associations exist for
depression and T2DM [17]. These conditions likely share
a common diathesis whereby the vulnerability factors for
depression and anxiety can contribute to the onset of
other disorders. Their mutually reinforcing nature may
lead to a progressive cycle of psychological and physical ill
health across the life course [18]. Third, there is accumu-
lating evidence that the same four lifestyle risk factors,
poor diet, physical inactivity, smoking and alcohol use,
also contribute to the onset and trajectory of the CMDs in
some important ways (explored in further detail in the
next section). These risk factors are likely to cluster and
further exacerbate the risk of other medical conditions as-
sociated with poor mental health. While beyond the scope
of this paper, the same is true for some of the serious
mental illnesses such as schizophrenia and bipolar dis-
order. In these, diet [19], smoking [20], substance and al-
cohol abuse and physical inactivity [21] adversely modify
risk or prognosis. Risk factor clustering is more common
among people with a CMD than in the non-CMD popula-
tion [22]; for example, alcohol consumption is closely as-
sociated with smoking, obesity and poor diet in depressed
populations [23]. Indeed, the potency of these risk factors
is likely to be multiplicative as they interact to increase the
risk of CMD onset. An individual’s susceptibility to a par-
ticular risk factor, and its magnitude of effect on disease
progression, will also differ according to their risk factor
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while poor lifestyle choices such as smoking may be inde-
pendent risk factors for CMDs [24], its effects are likely to
be pronounced in those pre-disposed to CMDs by genetic
or other environmental factors.
Shared risk factors and the high prevalence of co-
morbidity between NCDs and CMDs provide clear
support for the implementation of a shared framework
for the prevention and treatment of NCDs and CMDs.
Within the CDC’s three framework objectives, we now
consider key ways in which this agenda could be
advanced.
Obtain better scientific information: Greater intellectual and
financial investment into research specifically around the
primary prevention of CMDs as a key strategy for minimizing
subsequent NCD risk by delaying or preventing its onset
Many of the greatest victories in oncology and cardiology
have come through prevention rather than treatment ad-
vances. Public health policies around smoking, and risk
factor surveillance such as dyslipidaemia, hypertension
and pap smear tests being notable exemplars. When com-
pared with other disciplines of medicine, psychiatry has
arguably lagged behind in the field of prevention science.
Not withstanding recent indications that diet, vitamin D,
smoking and exercise may be important factors in the
onset of the CMDs (e.g. [25]), there remains a clear need
identify and quantify plastic risk factors that are germane
to psychiatric disorders. Large-scale, population-based
studies with the power to calculate the population attrib-
utable risk of specific CMDs from modifiable risk factors
(akin to the INTERHEART (2003) study for myocardial
infarction [26]) are critical for guiding population-wide
NCD prevention and control strategies, particularly for
the primary prevention of CMD. These data could also
guide the development of equivalent risk factor equations,
assessment tools and treatment algorithms for CMD pre-
vention that are often used in other areas of medicine for
guiding investment and resource allocation. While some
have attempted to develop risk algorithms based on indi-
vidual and collective risk factors to predict future risk of
depression and anxiety [27], they have not been developed
based on international data and, despite demonstrating
sound psychometric properties, are not routinely used in
clinical practice. The development and dissemination of
such materials could aid physicians and public health
practitioners in a range of health care settings to identify
those at high risk of CMD. Similarly, given the well-
established and respective links between depression and
incident CHD and T2DM, for example, widely used risk
assessment tools such as the Framingham Risk Equation
(for 10 year CVD risk) and AUSDRISK (for 5-year diabetes
mellitus risk) could be updated to include depression
parameters.Explication of the shared biological pathways under-
pinning the risk for commonly-comorbid psychological
and somatic illness will greatly advance the ability to de-
velop effective preventive strategies for both. For ex-
ample, immune system dysfunction is a common feature
of virtually all NCDs as well as depression. Related to
this understanding is the new knowledge regarding the
human gut microbiome as the core driver of immune
functioning, as well as the development of the brain,
metabolic and innate immune system in early life. Indeed,
there is emerging evidence to suggest that the main envir-
onmental risk factors implicated in the increasing preva-
lence of NCDs, ie. poor diet and sedentary behavior,
mediate their effects through immune pathways, with
downstream effects on insulin resistance, obesity, cardio-
vascular disease, as well as mood and behavior. New in-
sights in this rapidly developing field point to the utility of
taking population-level primary prevention approaches to
both NCDs and CMDs.
Disseminate the information to appropriate audiences:
Re-conceptualize discourse around CMDs within the context
of NCDs and educate health professionals, patients and
stakeholders accordingly
There is little doubt the way in which key stakeholders
from health professionals, industry, government to pa-
tients, conceptualise CMDs and NCDs, is vast; there is a
spectrum over which these conditions can be viewed.
Using the example of diabetes and depression, Fisher et al.
(2012) describes the different ways of conceptualising
NCDs and CMDs for prevention and treatment: as “a) cat-
egories or dimensions; b) single problems or parts of
broader categories, e.g., metabolic/cardiovascular abnor-
malities or negative emotions; c) separate comorbidities or
integrated so that depression is seen as part of the com-
prehensive, normal clinical picture of diabetes; and d) ex-
pressions of a shared, complex biosocial propensity to
chronic disease and psychological distress” [18]. He subse-
quently argues successful models of interventions should
reflect this, and the commonalities among chronic mental
and physical disorders [18].
Such integrated models of care already exist. For ex-
ample, a key component of the IMPACT model is the
education and upskilling of health care professionals to
identify, appropriately refer and communicate with pa-
tients about symptoms of CMDs. This approach has
largely been used for the concurrent management of de-
pression, CHD and T2DM in primary care settings [28]
and has shown to be more effective and cost-effective for
chronic disease management than standard care. Practice
Nurses are educated to act as case managers who aim to
provide continuity of care. They are trained to: encourage
support and effective communication to patients from cli-
nicians, utilizing evidence-based guidelines to promote
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ing visits and providing audit information [29]. However,
such models however have been subject to criticism.
For example, some have argued that integrated care
models have limited generalizability, require a cultural
shift in norms and roles, are too resource intensive to
implement, and create unnecessary overlap with other
related programs [30]. However, there are data that
refute some of these suggested barriers. Rollman et al.
has shown a similar ‘upskilling’ model when enacted
over the telephone to be generalizable to more specialized
populations. The Bypassing the Blues study found this
model efficacious for reducing depression in patients
undergoing coronary artery bypass grafting surgery [31].
Further, others have shown it to be scalable. Using a
cluster-randomised design in general practices across
Australia, the TrueBlue study provided evidence that with
sufficient training and ongoing support such as planning
tools and peer support, upskilling and educating Practice
Nurses can be effective for the management of co-morbid
depression, CHD and/or diabetes as well as fostering a
therapeutic alliance with (and education) of patients [32].
Indeed, the education of students, graduates and health
professionals and stakeholders on evidence based pro-
grams in this area is required to perpetuate a culture that
re-conceptualises the idea that CMDs and NCDs are
largely individual conditions. It is acknowledged however
that the scalability of models such as the aforementioned
remain dependent largely on local culture, health systems,
workforce and many other contextual factors and influ-
ences; all of which affect the adaptation of these types of
models within real world settings.
Translate the information into action: Develop appropriate
interventions and prevention programs considering context,
cost, responsibility and translation
An integrated framework that considers both CMDs
and NCDs needs to operate within existing structural,
organizational, cultural and economic barriers within
existing health care systems. For example, while case
management systems have long been used in primary
care settings to promote risk factor reduction in patients
with NCDs, arguably the most important characteristic
underpinning collaborative care models such as IMPACT
is its ability to capitalise on existing workforce and fi-
nancial infrastructures by refocussing the roles of the
existing members and organisational structures of the
setting. Fisher et al. [3] maintains that failure to con-
sider these contextual factors can result in a number of
potentially deleterious outcomes. First, efficacy and/or
effectiveness of specific interventions may be diluted.
Second, the benefits of interventions may be further
underestimated should contextual moderators remain
unaccounted for in analyses. Third, individuals participatingin these interventions could be perceived as responsible for
their condition resulting in a type of ‘victim blaming’ [3].
To this end, future opportunities exist to explore and evalu-
ate different approaches to increase awareness and under-
standing of these issues in both health professionals and
patient populations.
Currently, the health care system is faced with sig-
nificant and increasing pressure including the demands
of a higher prevalence of CMD [32] and NCDs which
is further compounded by other important factors like
the obesity and metabolic syndrome epidemics. Some
have argued that, despite a long and complicated history,
continuing to regard CMDs as an independent health do-
main, with siloed budgets and services, perpetuates the
notion that mental health investment has unaffordable
opportunity costs [3]. This points to the critical need to
explore shared and more efficient approaches to CMD
treatment and widen the current focus on treatment of
CMDs to give equal weight to prevention strategies;
many of which overlap with NCD prevention. However,
the perceived cost associated with the primary prevention
of diseases, much less that of CMDs, remains a barrier to
investment in this area. A WHO report suggests a key fac-
tor underscoring the traditional focus on, and preference
for, curative strategies are the short-term, tangible benefits
as opposed to the longer pay-off periods that are required
to see the effects of prevention [31]. This is particularly
evident as the cost of healthcare increases globally,
thereby increasing competition for resources [31].
Where to from here: translation into policy and practice?
From a policy perspective, a trans-disciplinary effort is
required from both the key stakeholders within the men-
tal health, public health and medical sector to provide a
collective voice if public policy in this arena is to be suc-
cessfully changed. Currently, policy development in areas
that are known to impact lifestyle behaviours (e.g. food
policy, taxation) in countries such as Australia is heavily
influenced by industry and the business sector. To this
end, the voice of mental health advocates becomes more
important for promoting the shared framework agenda.
Practically, a greater focus on the integration of mental
health research into services, leverage from existing in-
frastructure, lobbying for greater financial investment
for research and design and a greater input on mental
health outcomes within medicine may facilitate better
availability and translation of research findings around
prevention and control of CMDs to the policy arena.
The benefits of a shared approach to CMD and NCD:
beyond the health care system
The wellbeing and health benefits resulting from invest-
ment in prevention science is of clear economic importance
[33], particularly considering the associated costs largely
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(e.g., specialist care, hospital care and medication) and
lost productive time. A substantial economic burden
from NCDs is borne by workplaces, in particular, the
loss in productivity resulting from sickness absence and
continuing to work when ill, a behavior known as present-
eeism [34]. Additionally, a sizeable minority of employed
people with NCDs, an estimated 18% in Australian em-
ployees, will also be managing another major health
conditions including heart disease, arthritis, depres-
sion, asthma, and diabetes [34]; multimorbid disease
combinations which commonly include depression [35].
Further, data demonstrate absenteeism is higher amongst
people with one or more chronic illnesses, employees with
a chronic illness have higher rates of long-term work-
disability than the general population [36], and, as one
recent Australian study demonstrated co-morbid psy-
chological distress causes an increased risk of product-
ivity loss, from both absenteeism and presenteeism, for
a range of health conditions. Therefore, with an ageing
global workforce, a greater understanding of how to
promote the health, continued workforce participation
and subsequent productivity of workers with multiple
NCDs is a priority, as the impact of multimorbidity is not
restricted to older adults outside the working population.
To date, most of the research on multimorbidity and
health and social outcomes has focused on quality of life
[37], use of medical services [38], and hospitalisation
and mortality [39]. Further, the majority of research has
been conducted within clinical or primary care [35,40],
or selected older adult populations [40]. Given that many
NCDs affect healthier, working age adults [34], this focus
on clinical populations, and clinical outcomes, provides
insufficient evidence to inform public health approaches
to improving the health of the workforce [35,41]. There-
fore, increased focus needs to be on developing: i)
evidence-based guidance to inform a reduction of the
burden of common NCDs and co-morbid CMDs among
working age adults; ii) the prevention of long-term work
absences and the associated costs and generally poor
outcomes of return-to-work programmes and; iii) the
development of decision aids for individuals, their em-
ployers and their clinicians to help guide management
of work demands and work attendance.
Conclusion
There is a need to close the gap between the epidemic
growth of CMDs, like depression and anxiety, and NCDs,
such as type 2 diabetes and cardiovascular diseases, and
the provision of appropriate healthcare and public health
programs that address the shared determinants and path-
ways of these disorders. A shared framework for disease
prevention and control appears warranted, yet there
remains a range of contextual and economic factors toconsider for wide-scale implementation in real world
settings. Specific considerations include the responsibility
of investment and cost recovery, and better education of
key stakeholders. Intellectual and financial investment in
research remains an imperative, in order to advance our
understanding of the epidemiology, etiology and determi-
nants of mental conditions both independently and as
they relate to physical disorders.
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